IP Verse

Boehringer Ingelheim Rcv Gmbh & Co Kg / Boehringer Ingelheim International Gmbh opposition analysis

COMPANY ANALYSIS

Latest oppositions filed by Boehringer Ingelheim Rcv Gmbh & Co Kg / Boehringer Ingelheim International Gmbh

Patent Number:
EP3342786
Title:
Anti-Dll3 Antibody
Applicant:
CHUGAI SEIYAKU KABUSHIKI KAISHA
Opposition Date:
Mar 22, 2022
Patent Number:
EP3177645
Title:
Subcutaneously Administered Bispecific Antibodies For Use In The Treatment Of Cancer
Applicant:
LINDHOFER, HORST, DR.
Opposition Date:
Nov 16, 2021
Patent Number:
EP2820151
Title:
Cancer Patient Selection For Administration Of Wnt Signaling Inhibitors Using Rnf43 Mutation Status
Applicant:
IRM LLC
Opposition Date:
Dec 15, 2020
Patent Number:
EP2847223
Title:
Anti-B7-H6 Antibody, Fusion Proteins, And Methods Of Using The Same
Applicant:
TRUSTEES OF DARTMOUTH COLLEGE
Opposition Date:
Dec 20, 2019
Patent Number:
EP2647707
Title:
Cytotoxicity-Inducing Therapeutic Agent
Applicant:
CHUGAI SEIYAKU KABUSHIKI KAISHA
Opposition Date:
Jun 12, 2019
Patent Number:
EP2530091
Title:
Anti-Dll3 Antibody
Applicant:
CHUGAI SEIYAKU KABUSHIKI KAISHA
Opposition Date:
Jan 2, 2019
Patent Number:
EP2567709
Title:
Molecules And Methods For Modulating Low-Density-Lipoprotein Receptor-Related Protein 6 (Lrp6)
Applicant:
NOVARTIS AG
Opposition Date:
Sep 25, 2018

Competitors of Boehringer Ingelheim Rcv Gmbh & Co Kg / Boehringer Ingelheim International Gmbh

CHUGAI SEIYAKU KABUSHIKI KAISHA

NOVARTIS AG

THE UNIVERSITY OF TOKYO

Want to track Boehringer Ingelheim Rcv Gmbh & Co Kg / Boehringer Ingelheim International Gmbh?

Feel free to send us a message here and we will get back to you